Koo BK, Kang J, Park KW, et al. - By conducting an investigator-initiated, prospective, randomised, open-label, multicentre trial in South Korea, researchers sought to compare head to head the efficacy as well as the safety of aspirin and clopidogrel monotherapy in patients aged at least 20 years who maintained dual antiplatelet therapy without clinical events for 6–18 months following percutaneous coronary intervention with drug-eluting stents (DES). Participants were randomized (1:1) to receive a monotherapy agent of clopidogrel 75 mg once daily or aspirin 100 mg once daily for 24 months. A significant reduction in the risk of the composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and Bleeding Academic Research Consortium bleeding type 3 or greater was shown to be conferred by clopidogrel monotherapy, vs aspirin monotherapy, during the chronic maintenance period post-percutaneous coronary intervention with DES. Findings demonstrated the superiority of clopidogrel monotherapy over aspirin monotherapy in preventing future adverse clinical events in patients needing indefinite antiplatelet monotherapy post-percutaneous coronary intervention.